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Retinol May Promote Fluorouracil-Suppressed 
Healing of Experimental Intestinal Anastomoses
Jan Willem D. de Waard, MD; Theo Wobbes, MD, PhD;
Cees J. van der Linden, MD, PhD; Thijs Hendriks, PhD
Objectives: To examine the effects of perioperative ad­
ministration of fluorouracil on healing variables of in­
testinal anastomoses and to explore ways to promote re­
pair under these conditions.
Design: Seven-day, prospective randomized experimen­
tal trial.
Setting: Animal research laboratory.
Anim als: Male young-adult Wistar rats after resection 
and anastomosis of both ileum and colon.
Interventions: Random assignment to groups receiv­
ing placebo, daily fluorouracil (20 mg/kg per day, intra- 
peri to ne ally), daily fluorouracil plus retinol palmitate 
(5000 lU/kg per day, orally), daily fluorouracil plus in­
terleukin-2 (2X106 IU/kg per day, subcutaneously), or 
daily fluorouracil plus granulocyte macrophage colony- 
stimulating factor on the first 4 days after operation (20 
jxg/kg per day, intraperitoneally).
M ain Outcome Measures: Anastomotic bursting pres­
sure, breaking strength, hydroxyproline content, and ex 
vivo collagen synthetic capacity.
Results: Administration of fluorouracil decreased 
anastomotic breaking strength by more than 40% and 
caused a shift in bursting site from outside to within the 
suture line. It also lowered anastomotic hydroxyproline 
content. The capacity for collagen synthesis, which was 
greatly enhanced in 4-day-old anastomoses from the 
control group, was significantly (P<.05) and specifi­
cally reduced. Concomitant administration of retinol 
resulted in restoration of strength and hydroxyproline 
content, particularly in the ileum. Interleukin-2 and granu­
locyte macrophage colony-stimulating factor did not 
improve fluorouracil-suppressed repair: both wound 
strength andcollagen content were similar in the iluoro- 
uracil, fluorouracil/interleukin-2, and fluorouracil/ 
granulocyte macrophage colony-stimulating factor 
groups.
Conclusion: Intraperitoneal administration of (luoro- 
uracil, delivered from the day of operation onward, 
severely reduces anastomotic strength at the end of the 
first postoperative week. This negative effect may be 
prevented by oral administration of retinol.
(Arch Surg. 1995;130:959-965)
N the W estern world, colorectal lorectal cancer, adjuvant therapy is highly 
cancer is the second most frequent indicated. Fluorouracil is the recommended 
malignant neoplasm after lung can- standard treatment and has remained the
More than half the patients with building block for adjuvant trials.2
this disease will die of it as a con- apy m can
sequence of locoregional or distant spread. cer routinely is withheld until weeks after
While surgery remains the only curative surgery. However, there exists an excel-
treatment modality for early-stage disease, lent rationale to start therapy in the imme-
the most important prognostic feature noted diale postoperative period.1 Theories of tu-
mor-c
'SIS ww
to date in colorectal cancer is the surgical 
pathologic stage of the tumor resected. At that cancer cells are. more susceptible to an-
95% of patients with Dukes ticancer therapy when the tumor burden is
A or Bj carcinoma of the colon are cured by small4 Numerous animal model studies 
surgical resection alone. However, patients have demonstrated that a primary tumor can 
with stage B2 disease have a 30% to 70%
survival
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therapy alone, and patients with stage C dis­
ease have only a 10% to 50% chance.1 In these
total patient population presenting with co-
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See Materials and Methods
on next page
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MATERIALS AND METHODS Retinol paimitate was given orally (by gavage) from the day 
before surgery onward in a dosage of 5000 IU/kg per day. 
Recombinant murine GM-CSF was dissolved in sodium 
ANIMALS phosphate, 20 mmol/L, pH 7.5; sodium chloride, 0.15 mol/L;
and rat albumin, 5 mg/mL. It was administered intraperi- 
Seventy male outbred Wistar/Cpb:WU rats, weighing between toneally immediately after surgery and on the next 3 days 
200 and 300 g, were used. They were housed with two ani- in a dosage of 5 (xg (2.5 mL of the solution) per day. Re­
combinant human interleukin-2 was reconstituted in wa­
ter and diluted with 5% wt/wt dextrose in water. It was given
mals per cage and had free access to water and standard labo­
ratory chow, which contained 21.7 IU retinol paimitate per
gram (diet AM II, Hope Farms, Woerden, the Netherlands). subcutaneously (0.25 mL of solution) once a day from the 
For the first experiment, in which anastomotic strength day of surgery onward in a dosage of 2 X106 IU/kg of body 
and hydroxyproline content were measured, the animals weight.
were randomly divided into five groups: a control group In previous experiments that used the current model for
(n=ll), a fluorouracil group (n=Il), and three groups (n=10 intestinal healing, we established that anastomotic repair is 
each) that received fluorouracil plus retinol, GM-CSF, or not affected by daily administration of placebo solutions, ei-
interleukin-2. All rats were killed 7 days after surgery. 
The second experiment, measuring collagen synthesis,
ther by gavage or by intravenous, intraperitoneal, or subcu­
taneous injection (T.H., unpublished data, 1990 and 1992).
consisted of three groups of animals (n=6 each): a control group, For this reason the animals in the present control groups re- 
a fluorouracil group, and a group that received fluorouracil ceived intraperitoneal saline solution daily, 
plus retinol. These rats were killed 4 days after surgery.
The study was approved by the Animal Ethics Re­
view Committee of the Faculty of Medicine, University of 
Nijmegen (the Netherlands).
OPERATIVE PROCEDURE
After an intraperitoneal injection of pentobarbital so­
dium, a midline incision was made, and 1 cm of both small 
and large bowel were resected at 15 cm proximal to the il­
eocecal junction and 3 cm proximal to the rectal perito- 
Fluorouracil was given intraperitoneally in a dosage of 20 neal reflection, respectively. Continuity was restored mi-
DRUG ADMINISTRATION
mg/kg of body weight. This is the same dosage used be- crosurgically by the construction of an inverted one-layer
fore12 and represents the highest dosage that, in combina- seromuscular end-to-end anastomosis with eight inter- 
tion with surgery, did not result in a significant mortality rupted sutures of 8-0 monofilament material (Ethicon,
rate. Fluorouracil was administered once a day, immedi- Somerville, Mass). The abdomen was closed in two layers
ately after surgery and on the next 6 days, at a concentra- with a continuous 3-0 silk suture for the fascia and with
tion of 1 mg/mL of saline solution. staples for the skin.
inhibit the growth of metastatic deposits and that its re­
moval can increase the growth rate of métastasés.5 Experi­
mental data indicate that the efficiency of adjuvant therapy 
is inversely proportional to the time interval between sur­
gery and therapy. Although, so far, limited information ex­
ists to support timing decisions in human neoplasms, the 
considerations mentioned above support the thesis that 
treatment with anticancer agents should begin at the day 
of surgery or as soon as possible thereafter.3,6,7
Patients will present with recurrent disease at the op­
erative site or the peritoneal surface and/or with hepatic mé­
tastasés and systemic métastasés. Although percentages in 
the literature vary widely, local recurrence is high..8 Ideally, 
an adjuvant surgical therapy should be effective at all sites 
of recurrence, bothlocoregional anclsystemic. However, elimi­
nation of recurrence at a particular anatomical site may ben­
efit a significant proportion of patients in terms of survival 
or quality of life. Regional administration of cytostatic agents 
is expected to reduce systemic passage and thus general toxic 
effects, allowing higher local concentrations. This fact is im­
portant in view of the fact that the fluorouracil response rate 
may depend strongly on dose intensity.9
A number of clinical studies using immediate (0 to
4 days) postoperative intraperitoneal administration of 
fluorouracil are in progress,10 and a current European Or­
ganization for Research and Treatment of Cancer Trial 
(protocol 40911) has one arm in which patients are treated 
intraperitoneally with fluorouracil in the perioperative
period (Gastrointestinal Tract Cancer Cooperative Group, 
unpublished data, 1992). In an animal model of colon 
cancer, intraperitoneal administration of fluorouracil 
prevents peritoneal and hepatic metastasis.11
As interest in immediate postoperative local and/or sys­
temic adjuvant fluorouracil therapy rapidly increases, it be­
comes essential to delineate its hazards for anastomotic heal­
ing and to develop strategies to prevent negative effects 
because leakage of intestinal anastomoses is a potentially 
devastating surgical complication.
It was shown before that administration of fluoroura­
cil on the day of surgery and the next 2 days does not sig­
nificantly reduce strength in experimental intestinal anas­
tomoses.u Recently, Graf et al13 reported that prolongation 
of the fluorouracil therapy impaired the healing of colonic 
anastomoses. The present study describes the effects of a 
7-day course of intraperitoneal administration of fluoro­
uracil on repair of both ileal and colonic anastomoses in the 
rat. In addi tion, we examine the potential beneficial effects 
of retinol paimitate, granulocyte macrophage colony- 
stimulating factor (GM-CSF), and interleukin-2.
•S I 1/IS
Only one animal (from the fluorouracil/retinol group) died 
prematurely, owing to faulty oral administration of the drug.
All animals lost weight after surgery. In all groups, av­
erage weight loss was 9% of body weight at the first day
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ANALYTICAL PROCEDURES according to a procedure validated before for rat intestinal
tissue.13,16 Briefly, freshly collected tissue explants of I to 2 
The rats were killed by an intraperitoneal overdose of pen- mm2 were incubated in a medium containing tritiated pro­
tobarbital sodium. After opening the abdominal wound and line for 3 hours, and the radioactivity inconjorated into total
identifying the anastomoses, the adhésions were eut as far as protein was measured. Subsequently, to determine proline in-
possible without injuring the intestine. An intestinal segment corporation into collagen, excess purified collagenase was 
with the anastomosis in the middle was removed, with the added. The radioactivity in the supernatant represents CDP
sutures left in place. This segment was attached to an infu­
sion pump filled with methylene blue-stained saline solution. 
The pressure was raised with an infusion rate of 4 mL/min and
as a measure of the amount of collagen synthesized. Subtrac­
tion of the radioactivity in the CDP fraction from that in 
total protein yields the incorporation into noncoilagenous
recorded graphically. Both the bursting pressure (the maxi- protein (N CP). The relative collagen synthesis (RCS) was cal-
mum pressure recorded immediately before sudden loss of culated with a formula17 that takes into account the enrich-
pressure) and the site of rupture were noted. Thereafter, the ment of proline in collagen compared with other proteins; 
segment was placed in a tensiometer, and the breaking strength
was recorded. Thus, both the bursting pressure and thebreak-
Percentage of RCS-(CDP/[(NCPX5.4) + CDP] 1X 100%
ing strength were measured in the sanie anastomotic segment. Incorporation is expressed on the basis of sample wet weight,
The validity of this procedure had been confirmed in a pilot DNA18 content, or protein19 content, 
experiment. In two series of animals, the breaking strength 
was measured directly or after the procedure to obtain the burst­
ing pressure. Similar values for the average breaking strength
were obtained in both series (B. M. de Man and T.H., unpub- The main questions to be answered were the following: are
STATISTICAL ANALYSIS
lished data, 1992). anastomotic strength and hydroxyproline levels reduced
The anastomotic segment was then cleaned from the in the four groups receiving fluorouracil when compared
surrounding tissue, and a 5-mm segment with the suture with the control group, and second, are these variables im-
line in the middle was collected. The samples were frozen proved in the fluorouracil/retinol, fluorouracil/GM-CSF, and
immediately and stored in liquid nitrogen until process- fluorouracil/interleukin-2 groups when compared with the
ing. After weighing, the samples were pulverized and ly- fluorouracil group? To correct for the fact that multiple com-
ophilized, and the hydroxyproline content was measured parisons were made, pairwise comparisons were done us-
as described before.14
In the second experiment, collagen synthetic capac­
ity in control segments (removed at operation) and anas­
tomotic tissue were quantitated by measuring the incor­
poration of proline into collagenase digestible protein (CDP)
ing a level of significance of a'= 2a/k, where k is the total 
number of pairwise comparisons. Thus, differences be­
tween groups (Figure 1 and Figure 2) were considered 
significant (a=.05) at P<a', where a'=.014. The test used 
was a one-tailed Wilcoxon test.
after surgery. Thereafter, animals in the control group started 
to gain weight again, and at death, their average weight was 
6% over the weight at surgery. Weight gain was retarded 
in the fluorouracil group (average weight at day 7 was 94% 
of weight at surgery, P=.0002 vs control group), whereas 
rats in the fluorouracil/GM-CSF and fluorouracil/ 
interleukin-2 groups lost progressively more weight, the 
average weight at day 7 being only 85% (P=.0007 vs fluo­
rouracil group) and 84% (P=.0006 vs fluorouracil group), 
respectively, of the weight at surgery. In the group that re­
ceived retinol in addition to fluorouracil, average weight
at day 7 was 98% of the initial weight (P=.0004 and P=.08 
vs control and fluorouracil group, respectively).
Average anastomotic breaking strength is depicted 
in Figure 1. Administration of fluorouracil resulted in sig­
nificantly reduced anastomotic strength: breaking strength 
was lowered by 41% in ileal anastomoses and by 44% in 
the colonic anastomoses. Addition of GM-CSF or inter­
leukin-2 did not improve anastomotic strength. If the ani­
mals were given retinol and fluorouracil, the resulting 
breaking strength was significantly higher than that in 
rats receiving fluorouracil only. Although mean values 
were still lower than those of the control group, the dif­
ference was not statistically significant.
Figure 3 shows the values for the bursting pres­
sure obtained from the individual animals. In some ani­
mals, notably those from the fluorouracil/interleukin-2 
group, it proved to be technically difficult to prepare the
»tot»
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Figure 1. Anastomotic breaking strength, Bars represent mean+SO values. 
Asterisk denotes significantly (? < « ',  where a '-.014 [see "Methods" 
section]) different from control group; dagger, significantly different from 
fluorouracil group; and double dagger, nearly significantly (a'<P<2cc') 
different from fluorouracil group.
anastomotic segment for this analysis. As a consequence 
of iatrogenic damage, no bursting pressure could be mea­
sured in three ileal and two colonic anastomoses from this 
group and in one ileal anastomosis from the fluorouracil 
group. In the control group, the bursting site was always
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Figure 2. Anastomotic hydroxyproline concentration and content. Bars 
represent mean+SD values. Asterisk denotes significantly (P<a’, where 
a'=.014 [see “Methods“ section]) different from control group; dagger, 
significantly different from fluorouracil group; and double asterisks, nearly 
significantly (a'<P<2al) different from control group.
outside the suture line, meaning that the actual value no 
longer reflects wound strength because the anastomoses 
had grown stronger than the adjacent tissue. This was not 
the case in the other groups. In the fluorouracil group, rup­
ture occurred within the anastomotic area in nine of 21 
cases, confirming the reduction of anastomotic strength 
also observed by measuring the breaking strength. A simi­
lar phenomenon was observed in the groups that re­
ceived additional GM-CSF or interleukin-2. Again, addi­
tion of retinol appeared to improve strength: in this group, 
only four of 18 wounds ruptured within the suture line. 
This effect is also apparent if the mean anastomotic burst­
ing pressures were calculated using only those cases in 
which, rupture occurred within the anastomosis. For in­
stance, for ileum, these mean±SD values were 94±38 
mm Hg (n=5) in the fluorouracil group and 190±40 (n=3), 
93±52 (n=6), and 123 ±44 (n=5) mm Hg in the fluoro- 
uracil/retinol, fluorouracil/GM-CSF, and fluorouracil/ 
interleukin-2 groups, respectively.
Tissue hydroxyproline levels were quantified as a mea­
sure of collagen levels, and the average values for hydroxy­
proline concentration and content in a 5-mm anasto-
o
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Figure 3. Anastomotic bursting pressure. Symbols represent values from 
individual animals. Open circles indicate rupture within suture line; closed 
circles, rupture outside suture line. Group 1 is the control group (n-11); 
group 2; fluorouracil group (n-11); group 3, fluorouracll/retinol palmitate 
group (n=9); group 4, fluorouracil/granulocyte macrophage 
colony-stimulating factor group (n=1Q); and group 5, 
fluorouracil/interleukin-2 group (n=10).
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Collagen Synthesis Quantitation Basis
Figure 4. Increased collagen synthetic capacity in anastomoses. Bars 
represent the mean+ SD ratio (n=6) between ex vivo collagen synthesis 
measured in anastomotic tissue collected 4 days after surgery and 
uninjured intestine collected at surgery in animals from the control group. 
Values are calculated if synthesis is quantitated on the basis of wet weight, 
DNA content, or protein content or as relative collagen synthesis.
same
true for the fluorouracil/GM
motic segment are shown in Figure 2. In the fluorouracil interleukin-2 group. Addition of retinol appeared to pre-
group, anastomotic hydroxyproline concentration and con- hydroxyprolir
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Table 1. Ex Vivo Synthesis of Collagen and Noncollagen Protein In Ileal Anastomoses
Collagen 
DNA, dpm/jjig 
Wet weight, dpm/mg 
Protein, dpm/mg 
Percentage of RCS
Control Group
182±70 
440±124 
14 481 ±5302 
1.53±0,64
$
I-.'. >v . : :. . :. r;.'. . ;  *:;v •<«*. : V.  ^ X : ;• • h ;
Fluorouracil Group
Fluorouracil/ Retinol 
Palmitate Group
97±22t 
266+511 
7261+1840f
0.76+0.44
82+17f 
225i60| 
7978+1184f 
0.74+0.18
DNA, dpm/jag
5622+1368
090
2794+ 777 
7782 ±3305 
206013+65 876
2065+326
5570+856
*Explants from anastomotic tissue were collected 4 days after surgery and incubated for 3 hours with 166.5 kBq tritiated proline. Collagen synthesis is 
expressed as radioactivity in collagenase digestible protein and as percentage of relative collagen synthesis (RCS). Noncollagen protein synthesis is expressed 
as radioactivity in noncoliagenous protein. Data represent average values (± SD) from six animals, dpm indicates disintegrations per minute. 
f  Significantly different from control group (Wilcoxon two-sample test).
limit the lowering of hydroxyproline content, induced in 
ileal anastomoses by fluorouracil.
We also compared the collagen synthetic capacity, 
measured ex vivo in tissue explants, in the control, fluo- 
rouracil, and fluorouracil/retinol groups. Anastomotic col­
lagen synthetic capacity was increased greatly 4 days af­
ter surgery. Figure 4  shows that, in the control group, 
absolute collagen synthesis was enhanced approxi­
mately 10-fold in ileal anastomoses and fourfold in co­
lonic anastomoses. Although synthesis of NCP was also 
stimulated (data not shown), the increase was relatively 
specific for collagen, as indicated by the considerable en­
hancement of the percentage of RCS.
The average anastomotic synthetic capacity in ileum 
and colon of the various groups is given in Table I and 
Table 2, respectively. Clearly, administration of fluoro- 
uracil resulted in a specific and significant reduction of col­
lagen production capacity. This effect was seen irrespec­
tive of whether synthesis was expressed on the basis of wet 
weight, DNA content, or protein content. The capacity to 
produce NCP was hardly affected. Administration of reti­
nol together with fluorouracil did not change the synthe­
sis in ileal anastomoses compared with administration of 
fluorouracil alone. In contrast, retinol appeared to stimu­
late collagen synthetic capacity in the colonic anastomo­
ses. If collagen synthesis was expressed on the basis of DNA 
or protein content or as RCS, values in the fluorouracil/ 
retinol group were significantly higher than in the fluoro- 
uracil group and no longer significantly different from those 
observed in the control group. In addition, the produc­
tion capacity for NCP appeared to be significantly lower 
in the fluorouracil/retinol group than in the control group.
Trials for adjuvant chemotherapy for colorectal cancer be­
gan in the 1950s. Until now, disappointing results have been 
obtained despite enormous preclinical and clinical re­
search efforts. For more than 30 years, fluorouracil has been 
the mainstay of therapy, and today it remains the most ef­
fective single agent in the treatment of this disease, al­
though a meta-analysis of phase III randomized control tri­
als showed only limited benefit to its use.20 Much attention 
is directed at examining methods of enhancing fluoroura-
cil efficacy through biochemical modulation. However, cur­
rent efforts to improve outcome are also directed at opti­
mizing fluorouracil treatment schedules with respect to 
dosage and timing and route of administration.
In relation to the aspect of timing, interest in im­
mediate postoperative fluorouracil therapy is growing. 
In an effort to reduce the incidence of hepatic metasta­
sis, several recent trials have explored the efficacy of peri­
operative portal vein infusion of fluorouracil.7 Also, a num­
ber of clinical studies using perioperative intraperitoneal 
administration of fluorouracil are in train (Glimelius and 
Pâhlman10 and the Gastrointestinal Tract Cancer Coop­
erative Group, unpublished data, 1992). Thus, research 
into the effects of perioperative fluorouracil on the heal­
ing of intestinal anastomoses is highly indicated.
It is to be expected that the occurrence of any nega­
tive effect of fluorouracil administration on anasto­
motic healing will depend on the time of administration 
with respect to surgery. Probably, postponement of 
therapy until after the cellular phase of healing, when the 
wound has gained sufficient strength, will prevent any 
danger for anastomotic insu f [ici ency. If treatment is started 
immediately after surgery, the chances for complica­
tions may increase. Still, Hillan et al21 concluded that early 
postoperative intraperitoneal administration (at 0 to 4, 
3 to 7, or 7 to 12 days after surgery) of fluorouracil does 
not impair the healing of experimental colonic anasto­
moses. However, a major drawback of their study is the 
fact that anastomotic strength was assessed only after 14 
days, whereas eventual detrimental effects in the first week 
when strength is still low under normal healing condi­
tions are of more potential significance. It was found that 
three intraperitoneal doses of fluorouracil (at 0 to 2 days
: sur not sie anas
tomotic breaking strength and collagen content of 3- or 
7-day-old intestinal anastomoses.12 Our data show that 
continuation of treatment may result in a severe reduc­
tion of both anastomotic bursting pressure and break­
ing strength at 7 days after surgery. This outcome agrees 
with the recent findings of Graf et al,u who reported re­
duced breaking strength of colonic anastomoses after a 
similar fluorouracil regimen.
Assuming that wound strength is ultimately de­
cided by collagen (either its quantity or its quality),
ARCH SURG/VOL130, SEP 1995
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Table 2. Ex Vivo Synthesis of Collagen and Noncollagen Protein in Colonie Anastomoses*
Collagen 
DNA, dpm/jxg 
Wet weight, dpm/mg 
Protein, dpm/mg 
Percentage of RCS 
Noncollagen
DI\IA, dpm/|xg
Wet weight, dpm/mg 
Protein, dpm/mg
Control Group Fluorouracil Group
Fluorouracil/ Retinol 
Palmitate Group
201 ±90 
870±436 
20 667 ±9999 
2.18 ±0,95
102±36t
423±154t
9914±2936t
1.30±0.41
151±32t
529±91
18243±3536t
2.29±0.44t
1690±274 
7274±1710 
177 248±24 655
1440+307 
6033±1420 
141 355+23 873f
1175±80f
143 362±15244i
'* Explants from anastomotic tissue were collected 4 days after surgery and incubated for 3 hours with 166,5 kBq tritiated proline. Collagen synthesis is 
expressed as radioactivity in coiiagenase digestible protein and as percentage of relative collagen synthesis (RCS). Noncollagen protein synthesis is expressed 
as radioactivity in noncollagenous protein. Data represent average values (±SD) from six animals, dpm indicates disintegrations per minute. 
t  Significantly different from control group (Wilcoxon two-sample test). 
i Significantly different from fluorouracil group (Wilcoxon two-sample test).
changes in collagen metabolism are expected to affect 
anastomotic strength. The capacity for anastomotic col­
lagen synthesis in the fluorouracil group was only half 
that in the control group. This may explain the reduced 
anastomotic hydroxyproline content, although we can­
not yet preclude the possibility of concomitant in­
creased degradation of existing collagen fibers. It thus 
seems likely that a diminished presence of collagen con­
tributes to loss of strength, as observed in the fluoro­
uracil group, although changes in its quality, eg, the de­
gree of cross-linking, may also play a role.
Wound collagen synthesis is primarily a task for the 
fibroblast. Suppressed synthesis by fluorouracil adminis­
tration may be due to a direct toxic effect on fibroblasts or 
to suppression of regulatory inflammatory cells like T lym­
phocytes and macrophages. The latter play a central role 
in the repair sequence.22'23 Chemotherapy is known to de­
crease the number of monocytes. In earlier experiments, 
indications that a perioperative regimen of cytostatic drugs, 
including fluorouracil, delays the appearance of macro­
phages in the anastomotic area were found.24 Because re­
combinant murine GM-CSF has been reported to induce 
monocytosis and to increase the number of tissue macro­
phages,25,26 it seemed worthwhile to investigate whether ad­
ministration of this compound could ameliorate fluoro- 
uracil-impaired healing. However, when given for 4 
consecutive days from the day of surgery onward in a dose 
that had been proven effective in eliciting the desired he- 
mapoietic response in rodents 25,26 it did not improve heal­
ing. The animals in the fluorouracil/GM-CSF group lost pro­
gressively more weight than did those in the fluorouracil 
group, and anastomotic repair was not stimulated. If any­
thing, anastomotic bursting pressure and hydroxyproline 
levels were reduced even further.
Major surgery impairs the cellular immune 
response. It has been suggested that fluorouracil-based 
chemotherapy is associated with suppression of immune 
function.27 Thus, perioperative fluorouracil therapy might 
result in depressed function of macrophages and T lym­
phocytes. Stimulation of these cells might improve fluo- 
rouracil-suppressed healing. Interleukin-2, which 
supports the growth and function of activated T cells and 
macrophages, has been reported to improve cutaneous heal­
ing in rats treated with doxorubicin hydrochloride (Aclria- 
mycin).28 Interleukin-2 reverses the deleterious effects, sup­
posedly caused by immunosuppression, of blood transfusion 
on anastomotic healing.29 Perioperative immunotherapy 
with interleukin-2 has been suggested as a means to im­
prove the cellular immune system of patients undergoing 
surgery for colorectal cancer.30 Still, daily administration 
of interleukin-2 to the fluorouracil-treated rats in a dose 
that effectively stimulated transfusion-suppressed healing 
did not improve anastomotic healing: wound strength and 
collagen content were similar in the fluorouracil and fluo- 
rouracil/interleukin-2 groups.
Retinol is one of the retinoids that have a profound im­
pact on many biological functions. The apparent antitumor 
effects of retinoids have generated renewed enthusiasm for 
their application in clinical studies for oncologic therapeu­
tic indications.31 The healing-promoting capacity of reti­
nol, especially under conditions that retard repair, has been 
reported repeatedly. It has been shown to improve various 
aspects of healing in experimental cutaneous wounds in 
which repair was suppressed by steroids,32 induced diabe­
tes,33 irradiation,34 or tumor implantation.35 With regard to
mentation mitigated the negative effects of preoperative ir­
radiation on the bursting pressure and hydroxyproline con­
centrati on in 7-day-old rat colonic anastomoses. Interpre­
tation of their data is hampered because no data on bursting 
site were supplied. The same is true for a recent report that 
showed thathigh-dose retinol therapy reversed the inhibi­
tory effects of long-term administration of corticosteroids 
on the healing of ileal and colonic anastomoses.37
Our may
be useful in preventing the loss of early anastomotic strength 
that is induced by the use of cytostatic drugs administered 
from the day of surgery onward. Although all animals did 
receive retinol in their standard diet (up to an estimated 
800 IU/kg per day), administration of additional retinol en­
hanced anastomotic breaking strength in animals receiv­
ing fluorouracil. It also improved the bursting pressure, re­
ducing the frequency of bursting that occurred within the 
suture line. In those anastomotic segments in which the 
bursting site was within the anastomosis, the actual burst­
ing pressures measured were higher in the fluorouracil/
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etinol group than in the fluorouracil group. It is conceiv- 
ble that augmentation of the retinol dose may further 
nhance its efficacy. The dose given, 5000 IU/kg per day,
5 well below those administered to reverse the negative ef- 
ects of corticosteroids on wound repair.3738
The mechanism by which retinol antagonizes the ef- 
ect of fluorouracil remains to be elucidated. Retinol admin- 
stration may enhance the early inflammatory reaction to 
vcmnding, increasing the number of monocytes and mac- 
ophages at the injury site.39 Speculation also exists regard- 
ng stimulation of collagen synthesis and inhibition of col- 
agen degradation (Weinzweig et al35 and Phillips et al37). 
Ve have found no consistent support for a stimulation of
:ollagen synthesis. In ileal anastomoses, the collagen syn-
etmol groups, whereas the average anastomotic hydroxy-
rroup). In the colon, the collagen synthetic capacity was higher
vhereas the hydroxyproline content was similar in both 
groups. It should be emphasized that the hydroxyproline 
:cmtent was measured in a 5-mm segment containing un- 
njured tissue next to the suture line. Thus, small and local 
:hanges in either collagen degradation or collagen synthe- 
;is may remain undetected. Whatever mechanism is respoli­
able for the gain in wound strength, the beneficial effects 
)bserved in the present s tudy seem to be of potential clini- 
:al interest and warrant further investigation.
In summary, daily intraperitoneal administration of 
luorouracil from the day of surgery onward considerably 
educed anastomotic strength after 7 days. This may have 
)een caused by a reduction in collagen synthetic capac- 
ty  within the wound area. Loss of strength could not be 
jrevented by additional administration of GM-CSF or 
nterleukin-2, but the negative effects of fluorouracil were 
imeliorated by oral administration of retinol.
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